Discover and read the best of Twitter Threads about #HER2

Most recents (12)

@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc 2/4 #TumorBoardTuesday
Thurs Case🎀

#HER2+ #BreastCancer
✅Localized, early ➡️neoadj tx w chemo + anti-HER2
✅⬆️DFS w T-DM1 for residual disease
✅Future role for T-DXd?

📚We captured @drteplinsky’s discussion in this moment:…
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc 3/4 #TumorBoardTuesday
Thursday Case🎀

📷 TBT in an image: Take a 👀at a (simplified) guide to treatment of early stage HER2+, localized #BreastCancer!

We review KATHERINE and use of ADCs to improve OS with residual disease. Is there an evolving role for T-DXd? Image
@TumorBoardTues @drteplinsky @MPishvaian @PTarantinoMD @DFCI_BreastOnc @KariWisinski_MD @JaniceTNBCmets @her2bc @dradityabardia @EricaMarieRomn1 @jacobadashek @esinghimd @BreastCaupdates 4/4 #TumorBoardTuesday
Thurs Case🎀

🙏 Anti-HER2+ tx in neoadj setting improves pCR. T-DM1 improves OS when residual disease is present.
🤔 Role for other ADCs or even neoadj setting?

➡️Be sure to join us 11.01.22 when @LeciaSequist presents a case of ALK+ #NSCLC #LungCancer
Read 8 tweets
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic 2/4 #TumorBoardTuesday
Thurs Case🎀
✅Wait on NGS- IO +TKI=⬆️tox
✅Osimertinib= ex19, 21m
✅New ADCs, small molecules= future options
✅ Re-bx on prog EGFRm- rule out small cell transformation

📚We captured @n8pennell’s discussion:…
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic 3/4 #TumorBoardTuesday
Thursday Case🎀

📷 #TBT in an image: we’ve summarized some key pts re: EGFRm #NSCLC & emerging data- hope to see more ADCs as 3L options for pts with EGFRm disease in the future! Image
@TumorBoardTues @n8pennell @MPishvaian @ShrutiPatelMD @NarjustFlorezMD @OncBrothers @jillfeldman4 @Joshua_Reuss @JineshGheeya @ClevelandClinic @esinghimd @nihardesai7 @NicoGagelmann @drteplinsky @jacobadashek 4/4 #TumorBoardTuesday
Thurs Case🎀

🐟Thanks to @n8pennell for an excellent discussion about the future of #EGFRm directed therapy!

➡️Please be sure to join us in 2 weeks on 10/18/22 when @drteplinsky presents a case of
Early-stage #HER2+ #BreastCancer 😀
Read 7 tweets
Dr. @LauraMezquitaMD discusses the DESTINY-Lung02 data at #ESMO22
Trastuzumab deruxtecan (T-DXd) is an antibody drug conjugate (ADC) targeting #HER2 and in DESTINY-Lung01, RR was encouraging at 55% but some concern for toxicity (adjudicated drug-related ILD in 26% of cases). #ESMO22
In DESTINY-Lung02, we have a randomization of pts with #HER2 mt NSCLC (with prior therapy) to the 6.4 mg/kg dose used in DESTINY-Lung01 or a lower, 5.4 mg/kg dose. RR higher at 5.4 (due to maintained intensity from less tox? or imbalance in baseline characteristics?) #ESMO22
Read 5 tweets
Dr. Koichi Goto starts the lung mini oral session with results from DESTINY-Lung02 of the recently approved trastuzumab deruxtecan in #HER2 NSCLC #ESMO22
DESTINY-Lung02 compared two doses of trastuzumab deruxtecan (T-DXd) in #HER2 previously treated NSCLC (5.4 mg/kg vs 6.4 mg/kg): RR 58% and DoR 8.7m at the lower dose compared to 43% at 6.4 mg/kg. #ESMO22
Importantly- interstitial lung disease much less frequent at the 5.4 mg/kg dose (5.9%, only 1 case of G3). This is the FDA approved dose of trastuzumab deruxtecan in #HER2 NSCLC #ESMO22
Read 4 tweets
1/12 #TumorBoardTuesday
2L treatment in #HER2+ breast cancer #MBC is 🤯! @PTarantinoMD led us through latest evidence👩‍⚖️

➡️Here's the Thurs Case🎀
👉Grab🆓 #CME credit by answering quick❓
CME rationale🔗:
Here we go!
2/12 #TumorBoardTuesday
Thurs Case🎀

⬆️ options to tx HER2+ #MBC
✅T-DXd >T-DM1 in 2L setting (DESTINY BREAST-03)
✅Beware ADC tox- think 🫁pneumonitis & GI w T-Dxd
✅ADC design is 🗝:
➡️Need to consider DAR, linker, ability to cause ADCC
✅ADC + IO= open ❓
3/12 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages (cont’d):
✅T-DXd active against brain mets (TUXEDO-1)
✅Triplet (tucatinib, cape, tras) also active in brain mets
✅Next up: T-DXd in HER2 LOW- trials ongoing

📚We captured the discussion here:…
Read 15 tweets
💊💊 New Tweetorial Alert 💊💊
Please take a break from your #doomscrolling and read this thread. If you have an even longer break read the paper @NEJM:… 1/7
This paper is about #PartD & cancer. It is also about #pharmacoequity (shoutout @UREssien). Not the way we typically think about equity, though. This is about how screwed you are if you need cancer treatment and your treatment happens to be covered by #PartD and not #PartB. 2/7
Half of cancer drugs are covered by #PartD. Whether you get a pill versus infusion is based on your cancer type or subtype. For #breastcancer the preferred regimens for #HER2+ cancer are infused (#PartB); for HER2-, ER/PR+ cancer preferred regimens include a #PartD drug. 3/7
Read 8 tweets
#WCLC20 Dr. Nakagawa presents results from the DESTINY-Lung01 trial of trastuzumab deruxtecan (T-DXd, Enhertu). T-DXd is a HER2 antibody-drug conjugate (ADC). #LCSM @IASLC @OncoAlert
#WCLC20 This study had two cohorts. Here, we focus on Cohort 1 (HER2-overexpressing = IHC3+ or IHC2+). Primary response rate was ORR. #LCSM
#WCLC20 As a reminder, we saw results from Cohort 2 (HER2-mutant) at #ASCO20 where they reported an ORR of 61.9% with mPFS 14.0m, which led to the inclusion of T-DXd in the @NCCN guidelines for #HER2 mutant NSCLC. #LCSM
Read 8 tweets
#ESMO20 Update on poziotinib in #HER2 mutant #NSCLC by Mark Socinski from the ongoing phase II ZENITH20 study. #LCSM @OncoAlert @AdventHealth Image
#ESMO20 There are 7 cohorts to ZENITH20, 3 have completed accrual. This presentation focuses on cohort 2, #HER2 mutant NSCLC. Heavily pretreated population with most having received IO therapy and some with prior HER2 therapy as well. #LCSM @OncoAlert ImageImage
#ESMO20 Poziotinib in #HER2 mutant NSCLC had a response rate of 27.8%. Duration of response 5.1 months, median time on treatment 3.7 months, median PFS 5.5 months. #LCSM @OncoAlert Image
Read 6 tweets
#ESMO20 Happy to share the first results of RAIN-701, a phase II study of #tarloxotinib in patients with NSCLC harboring an #EGFR exon 20 insertion or an activating #HER2 mutation and any solid tumor with an #NRG1 or ERBB gene fusion. #LCSM @OncoAlert
#ESMO20 Tarlox is given as an inactive prodrug that embeds in the cell membrane. Only when it encounters hypoxia does it undergo single electron reduction to fragment to a cell permeable, pan-HER, irreversible TKI with subnanomolar potency at EGFR, HER2 and HER4. @OncoAlert #LCSM
#ESMO20 Top right shows the IC50 of Tarloxotinib-E in human cell lines, bottom right corroborate with additional mutations in BAF3 models. Note the differential target inhibition for Tarlox-E with a lower IC50 for #HER2 than EGFR and the lowest IC50 for #NRG1 fusions. #LCSM
Read 11 tweets
#ESMO20 Nice discussion of the #EGFR / #HER2 #NSCLC abstracts from @ZerAlona covering poziotinib, tarloxotinib, mobocertinib, and patritumab deruxtecan. #LCSM #OncoAlert Image
#ESMO20 @ZerAlona discusses the efficacy of these EGFR/HER2 TKIs, balanced by their toxicity relative to other agents #LCSM #OncoAlert ImageImageImage
#ESMO20 We are seeing promising activity with mobocertinib in EGFRex20, patritumab deruxtecan in sensitizing #EGFR, and tarloxotinib and poziotinib in #HER2, but some toxicity concerns with poziotinib at this dose schedule. Nice discussion @ZerAlona #LCSM #OncoAlert Image
Read 3 tweets
Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.

Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Read 55 tweets
#ASCO20 Important data for #HER2 #NSCLC from the DESTINY-Lung01 study of trastuzumab deruxtecan (T-DXd, DS-8201) in previously treated, HER2 mutant NSCLC. T-DXd is an antibody drug conjugate (ADC) with a topo-I inhibitor payload linked to a trastuzumab-like IgG1 mAb. #OncoAlert ImageImageImage
#ASCO20 Included 42 pts with #HER2 mut #NSCLC (45% with CNS metastases) treated with T-DXd 6.4mg/kg q3w. Impressive outcomes: ORR 62%, DCR 90%, mPFS 14 months! And 45% of patients still on treatment. #OncoAlert #LCSM ImageImageImageImage
#ASCO20 T-DXd led to nausea in most patients (largely G1-2). Alopecia in about half; anemia and neutropenia (some G3+) also observed. Treatment emergent AEs leading to discontinuation in 24% of patients. Grade 2 interstitial lung disease seen in 12% (median onset 86d). #OncoAlert ImageImageImage
Read 3 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!